BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, Boscolo Anzoletti M, De Zan V, Pagliari MT, Gualtierotti R, Aliberti S, Panigada M, Grasselli G, Blasi F, Peyvandi F. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 2021;19:513-21. [PMID: 33230904 DOI: 10.1111/jth.15191] [Cited by in Crossref: 31] [Cited by in F6Publishing: 76] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Root-bernstein R, Huber J, Ziehl A. Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies. IJMS 2022;23:11500. [DOI: 10.3390/ijms231911500] [Reference Citation Analysis]
2 Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. The association between mean platelet volume and poor outcome in patients with COVID-19: Systematic review, meta-analysis, and meta-regression. Journal of the Intensive Care Society. [DOI: 10.1177/17511437221121234] [Reference Citation Analysis]
3 Cabrera-Garcia D, Miltiades A, Yim P, Parsons S, Elisman K, Mansouri MT, Wagener G, Harrison NL. Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. Int J Hematol 2022. [PMID: 35994163 DOI: 10.1007/s12185-022-03437-2] [Reference Citation Analysis]
4 Xu X, Feng Y, Jia Y, Zhang X, Li L, Bai X, Jiao L. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis. Thromb Res 2022;218:83-98. [PMID: 36027630 DOI: 10.1016/j.thromres.2022.08.017] [Reference Citation Analysis]
5 Claireaux M, Caniels TG, de Gast M, Han J, Guerra D, Kerster G, van Schaik BDC, Jongejan A, Schriek AI, Grobben M, Brouwer PJM, van der Straten K, Aldon Y, Capella-Pujol J, Snitselaar JL, Olijhoek W, Aartse A, Brinkkemper M, Bontjer I, Burger JA, Poniman M, Bijl TPL, Torres JL, Copps J, Martin IC, de Taeye SW, de Bree GJ, Ward AB, Sliepen K, van Kampen AHC, Moerland PD, Sanders RW, van Gils MJ. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. Nat Commun 2022;13:4539. [PMID: 35927266 DOI: 10.1038/s41467-022-32232-0] [Reference Citation Analysis]
6 Chaudhary H, Nasir U, Syed K, Labra M, Reggio C, Aziz A, Shah P, Reddy R, Sangha N. COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review. Hematology Reports 2022;14:253-60. [DOI: 10.3390/hematolrep14030035] [Reference Citation Analysis]
7 Bray M, Guzel MA, Lam F, Yee A, Cruz MA, Rumbaut RE. High levels of von Willebrand factor with reduced specific activities in hospitalized patients with or without COVID-19. J Thromb Thrombolysis 2022. [PMID: 35881214 DOI: 10.1007/s11239-022-02679-5] [Reference Citation Analysis]
8 Dolgushina N, Gorodnova E, Beznoshenco O, Romanov A, Menzhinskaya I, Krechetova L, Sukhikh G. Von Willebrand Factor and ADAMTS-13 Are Associated with the Severity of COVID-19 Disease. JCM 2022;11:4006. [DOI: 10.3390/jcm11144006] [Reference Citation Analysis]
9 Lim S, Murphy S, Murphy S, Coughlan T, O'neill D, Tierney S, Egan B, Collins D, Mccarthy A, Lim S, Smith D, Cox D, Mccabe D. Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. Journal of the Neurological Sciences 2022. [DOI: 10.1016/j.jns.2022.120334] [Reference Citation Analysis]
10 Iba T, Wada H, Levy JH. Platelet Activation and Thrombosis in COVID-19. Semin Thromb Hemost 2022. [PMID: 35738296 DOI: 10.1055/s-0042-1749441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Zguro K, Baldassarri M, Fava F, Beligni G, Daga S, Leoncini R, Galasso L, Cirianni M, Rusconi S, Siano M, Francisci D, Schiaroli E, Luchi S, Morelli G, Martinelli E, Girardis M, Busani S, Parisi SG, Panese S, Piscopo C, Capasso M, Tacconi D, Spertilli Raffaelli C, Giliberti A, Gori G, Katsikis PD, Lorubbio M, Calzoni P, Ognibene A, Bocchia M, Tozzi M, Bucalossi A, Marotta G, Furini S, Renieri A, Fallerini C; GEN-COVID Multicenter Study. Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19. Viruses 2022;14:1185. [DOI: 10.3390/v14061185] [Reference Citation Analysis]
12 Mohan G, Wilson W, Paonam B, Vaidya A, Ravindra P, Shastry S, Balakrishnan JM, Rao S, Chaudhuri S. Utility of Thromboelastography and velocity curve derivative in diagnosing COVID-19 associated coagulopathy. Int J Lab Hematol 2022. [PMID: 35609623 DOI: 10.1111/ijlh.13876] [Reference Citation Analysis]
13 Osburn WO, Smith K, Yanek L, Amat-Alcaron N, Thiemann DR, Cox AL, Leucker TM, Lowenstein CJ. Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. PLoS One 2022;17:e0268296. [PMID: 35588115 DOI: 10.1371/journal.pone.0268296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Azukaitis K, Stankute-Kolosova A, Burokiene V, Saulyte Trakymiene S, Jankauskiene A. Possible microangiopathic overlap between COVID-19 and Shiga toxin-associated hemolytic uremic syndrome. Pediatr Blood Cancer 2022;:e29798. [PMID: 35593662 DOI: 10.1002/pbc.29798] [Reference Citation Analysis]
15 Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 2022;76:1291-305. [PMID: 35589251 DOI: 10.1016/j.jhep.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sadler B, Castaman G, O'Donnell JS. von Willebrand disease and von Willebrand factor. Haemophilia 2022;28 Suppl 4:11-7. [PMID: 35521725 DOI: 10.1111/hae.14547] [Reference Citation Analysis]
17 Yang X, Rutkovsky AC, Zhou J, Zhong Y, Reese J, Schnell T, Albrecht H, Owens WB, Nagarkatti PS, Nagarkatti M. Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients. J Immunol 2022;208:1968-77. [PMID: 35379747 DOI: 10.4049/jimmunol.2101099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Fujimura Y, Holland LZ. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm. Int J Hematol 2022. [PMID: 35316498 DOI: 10.1007/s12185-022-03324-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Sharma S, Mishra A, Ashraf Z. COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection. TH Open 2022;6:e70-9. [PMID: 35280973 DOI: 10.1055/s-0042-1744185] [Reference Citation Analysis]
20 Skalska-świstek M, Huras H, Jaworowski AP, Świstek R, Kołak M. COVID-19 Infection Complicated by Disseminated Intravascular Coagulation during Pregnancy—Two Cases Report. Diagnostics 2022;12:655. [DOI: 10.3390/diagnostics12030655] [Reference Citation Analysis]
21 Martínez-Salazar B, Holwerda M, Stüdle C, Piragyte I, Mercader N, Engelhardt B, Rieben R, Döring Y. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Front Cell Dev Biol 2022;10:824851. [PMID: 35242762 DOI: 10.3389/fcell.2022.824851] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
22 Billoir P, Leprêtre P, Thill C, Bellien J, Le Cam Duchez V, Selim J, Tamion F, Clavier T, Besnier E. Routine and Advanced Laboratory Tests for Hemostasis Disorders in COVID-19 Patients: A Prospective Cohort Study. JCM 2022;11:1383. [DOI: 10.3390/jcm11051383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lee M, Cornman-homonoff J, Madoff DC. Bronchial artery embolization for hemoptysis in a postpartum patient via cesarean section with COVID-19 while on extracorporeal membrane oxygenation. Clinical Imaging 2022;83:123-30. [DOI: 10.1016/j.clinimag.2021.12.017] [Reference Citation Analysis]
24 Montiel V, Lobysheva I, Gérard L, Vermeersch M, Perez-Morga D, Castelein T, Mesland JB, Hantson P, Collienne C, Gruson D, van Dievoet MA, Persu A, Beauloye C, Dechamps M, Belkhir L, Robert A, Derive M, Laterre PF, Danser AHJ, Wittebole X, Balligand JL. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine 2022;77:103893. [PMID: 35219085 DOI: 10.1016/j.ebiom.2022.103893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
25 Reyad KA, Abelhalim MM, Tallal RE. Prevalence of Deep Venous Thrombosis in Abdominoplasty Patients after COVID-19 Convalescence: An Alarming Flag. Plastic and Reconstructive Surgery - Global Open 2022;10:e4196. [DOI: 10.1097/gox.0000000000004196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Teimury A, Khameneh MT, Khaledi EM. Major coagulation disorders and parameters in COVID-19 patients. Eur J Med Res 2022;27:25. [PMID: 35168674 DOI: 10.1186/s40001-022-00655-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
27 Hamada E, Sakai K, Yamada S, Kubo M, Hayakawa M, Matsumoto M. No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey. Ann Hematol 2022. [PMID: 35119501 DOI: 10.1007/s00277-022-04774-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 O’donnell AS, Fazavana J, O’donnell JS. The von Willebrand factor – ADAMTS‐13 axis in malaria. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Thangaraju K, Katneni U, Akpan IJ, Tanaka K, Thomas T, Setua S, Reisz JA, Cendali F, Gamboni F, Nemkov T, Kahn S, Wei AZ, Valk JE, Hudson KE, Roh DJ, Moriconi C, Zimring JC, D'Alessandro A, Spitalnik SL, Francis RO, Buehler PW. The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. Front Med (Lausanne) 2021;8:817305. [PMID: 35087853 DOI: 10.3389/fmed.2021.817305] [Reference Citation Analysis]
30 Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Mező B, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality. Thromb Haemost 2022. [PMID: 35062036 DOI: 10.1055/s-0041-1740182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, Duerschmied D, Smyth SS, Parker WAE, Ajjan RA, Vilahur G, Badimon L, Berg JMT, Cate HT, Peyvandi F, Wang TT, Becker RC. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol 2022. [PMID: 35027697 DOI: 10.1038/s41569-021-00665-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 29.0] [Reference Citation Analysis]
32 Mizurini DM, Hottz ED, Bozza PT, Monteiro RQ. Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects. Front Cardiovasc Med 2021;8:785738. [PMID: 34977191 DOI: 10.3389/fcvm.2021.785738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
33 Seth R, McKinnon TAJ, Zhang XF. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. Am J Physiol Heart Circ Physiol 2022;322:H87-93. [PMID: 34890277 DOI: 10.1152/ajpheart.00204.2021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
34 Gotelli E, Paolino S, Soldano S, Cutolo M. Vitamin D Immune-Mediated Responses and SARS-CoV-2 Infection: Clinical Implications in COVID-19. Immuno 2022;2:1-12. [DOI: 10.3390/immuno2010001] [Reference Citation Analysis]
35 Gauchel N, Rieder M, Krauel K, Goller I, Jeserich M, Salzer U, Venhoff AC, Baldus N, Pollmeier L, Wirth L, Kern W, Rieg S, Busch HJ, Hofmann M, Bode C, Duerschmied D, Lother A, Heger LA. Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease. J Thromb Thrombolysis 2021. [PMID: 34904186 DOI: 10.1007/s11239-021-02617-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program 2021;2021:621-7. [PMID: 34889411 DOI: 10.1182/hematology.2021000298] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
37 Goswami J, Macarthur TA, Sridharan M, Tange J, Kirmse AJ, Lundell KA, Chen D, Auton MT, Chon TY, Hurt RT, Salonen BR, Ganesh R, Erben YM, Marquez CP, Dong J, Kozar RA, Heller SF, Loomis EA, Johnstone AL, Bailey KR, Spears GM, Park MS. Biomarkers of thromboinflammation correlate to COVID-19 infection and admission status in emergency department patients. Thrombosis Update 2021;5:100090. [DOI: 10.1016/j.tru.2021.100090] [Reference Citation Analysis]
38 Presnyakova MV, Zagrekov VI, Kostina OV, Pushkin AS, Kuznetsova VL, Arefyev IY. The effect of hyperoxia on the hemostasiological status of severely burned patients. Klin Lab Diagn 2021;66:666-72. [PMID: 34882351 DOI: 10.51620/0869-2084-2021-66-11-666-672] [Reference Citation Analysis]
39 Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. J Mol Cell Cardiol 2021;164:69-82. [PMID: 34838588 DOI: 10.1016/j.yjmcc.2021.11.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
40 Laubscher GJ, Lourens PJ, Venter C, Kell DB, Pretorius E. TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. J Clin Med 2021;10:5381. [PMID: 34830660 DOI: 10.3390/jcm10225381] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
41 Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M. High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med 2021. [PMID: 34741678 DOI: 10.1007/s10238-021-00769-x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Fogarty H, Karampini E, O'Donnell AS, Ward SE, O'Sullivan JM, O'Donnell JS; Irish COVID-19 Vasculopathy Study (iCVS) investigators. Persistent endotheliopathy in the pathogenesis of long COVID syndrome - Reply to comment from von Meijenfeldt et al. J Thromb Haemost 2021. [PMID: 34738307 DOI: 10.1111/jth.15578] [Reference Citation Analysis]
43 Baranowska-Kuczko M, Kozłowska H, Kloza M, Kusaczuk M, Harasim-Symbor E, Biernacki M, Kasacka I, Malinowska B. Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension. Pharmaceuticals (Basel) 2021;14:1120. [PMID: 34832902 DOI: 10.3390/ph14111120] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Gawaz M, Scharf RE. COVID-19: Cardio-pulmonary and Vascular Manifestations. Hamostaseologie 2021;41:347-8. [PMID: 34695851 DOI: 10.1055/a-1370-0231] [Reference Citation Analysis]
45 Root-Bernstein R. COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-binding proteins, platelet factor 4, prothrombin, and coagulation factors. Bioessays 2021;43:e2100158. [PMID: 34677872 DOI: 10.1002/bies.202100158] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
46 Chan M, Zhao X, Zheng XL. Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia. Res Pract Thromb Haemost 2021;5:e12581. [PMID: 34553121 DOI: 10.1002/rth2.12581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Mobayen G, Dhutia A, Clarke C, Prendecki M, McAdoo S, Keniyopoullos R, Malik T, Laffan M, Willicombe M, McKinnon T. Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis. Res Pract Thromb Haemost 2021;5:e12582. [PMID: 34532629 DOI: 10.1002/rth2.12582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Alavi P, Rathod AM, Jahroudi N. Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor. J Clin Med 2021;10:4190. [PMID: 34575297 DOI: 10.3390/jcm10184190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
49 Tiscia G, Favuzzi G, De Laurenzo A, Cappucci F, Fischetti L, Colaizzo D, Chinni E, Florio L, Miscio G, Piscitelli AP, Mastroianno M, Grandone E. The Prognostic Value of ADAMTS-13 and von Willebrand Factor in COVID-19 Patients: Prospective Evaluation by Care Setting. Diagnostics (Basel) 2021;11:1648. [PMID: 34573989 DOI: 10.3390/diagnostics11091648] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
50 Dushianthan A, Abdul N, Dmochowski J, James I, Heesom L, Westwood J, Effney J, Bruty S, Saeed K, Rangarajan S, Kazmi R. Predictive Role of Haematological Determinants on Outcomes of Critically Ill COVID-19 Patients Admitted to Intensive Care Unit. Cureus 2021;13:e16764. [PMID: 34476137 DOI: 10.7759/cureus.16764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Alhomoud M, Alhobayb T, Armitage K. COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura. IDCases 2021;26:e01256. [PMID: 34458098 DOI: 10.1016/j.idcr.2021.e01256] [Reference Citation Analysis]
52 Francischetti IMB, Toomer K, Zhang Y, Jani J, Siddiqui Z, Brotman DJ, Hooper JE, Kickler TS. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine 2021;39:101069. [PMID: 34377969 DOI: 10.1016/j.eclinm.2021.101069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
53 Becker RC, Sexton T, Smyth S; International COVID-19 Thrombosis Biomarkers Colloquium (ICODE) Investigators. COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles. J Thromb Thrombolysis 2021. [PMID: 34350541 DOI: 10.1007/s11239-021-02544-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Levy JH, Iba T, Olson LB, Corey KM, Ghadimi K, Connors JM. COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. Int J Lab Hematol 2021;43 Suppl 1:29-35. [PMID: 34288441 DOI: 10.1111/ijlh.13500] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
55 Joly BS, Darmon M, Dekimpe C, Dupont T, Dumas G, Yvin E, Beranger N, Vanhoorelbeke K, Azoulay E, Veyradier A. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients. J Thromb Haemost 2021;19:2193-8. [PMID: 34219357 DOI: 10.1111/jth.15445] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
56 Veluswamy P, Wacker M, Stavridis D, Reichel T, Schmidt H, Scherner M, Wippermann J, Michels G. The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. Viruses 2021;13:1346. [PMID: 34372552 DOI: 10.3390/v13071346] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
57 Goshua G, Butt A, Lee AI. Immunothrombosis: a COVID-19 concerto. Br J Haematol 2021;194:491-3. [PMID: 34114208 DOI: 10.1111/bjh.17666] [Reference Citation Analysis]
58 Tripodi A, Rossi SC, Clerici M, Merati G, Scalambrino E, Mancini I, Baronciani L, Boscarino M, Monzani V, Peyvandi F. Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. Clin Chem Lab Med 2021;59:1699-708. [PMID: 34192831 DOI: 10.1515/cclm-2021-0538] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Smadja DM, Mentzer SJ, Fontenay M, Laffan MA, Ackermann M, Helms J, Jonigk D, Chocron R, Pier GB, Gendron N, Pons S, Diehl JL, Margadant C, Guerin C, Huijbers EJM, Philippe A, Chapuis N, Nowak-Sliwinska P, Karagiannidis C, Sanchez O, Kümpers P, Skurnik D, Randi AM, Griffioen AW. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis 2021. [PMID: 34184164 DOI: 10.1007/s10456-021-09805-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 35] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wibowo A, Pranata R, Lim MA, Akbar MR, Martha JW. Endotheliopathy Marked by High von Willebrand Factor (vWF) Antigen in COVID-19 is Associated with Poor Outcome: A Systematic Review and Meta-analysis. Int J Infect Dis 2021:S1201-9712(21)00540-3. [PMID: 34192577 DOI: 10.1016/j.ijid.2021.06.051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
61 Ward SE, Fogarty H, Karampini E, Lavin M, Schneppenheim S, Dittmer R, Morrin H, Glavey S, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Mallon PW, Curley GF, Baker RI, Budde U, O'Sullivan JM, O'Donnell JS; Irish COVID-19 Vasculopathy Study (iCVS) investigators. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021;19:1914-21. [PMID: 34053187 DOI: 10.1111/jth.15409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
62 Bhogal P, Makalanda L, Hassan AE, Fiorella D, Andersson T, Ahmad M, Bäzner H, Jaffer O, Henkes H. COVID-19 and Delayed Cerebral Ischemia-More in Common Than First Meets the Eye. J Clin Med 2021;10:2646. [PMID: 34208470 DOI: 10.3390/jcm10122646] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Bhogal P, Paul G, Collins G, Jaffer O. Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021;24:413-5. [PMID: 34101095 DOI: 10.1007/s10456-021-09790-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
64 Pistor M, Hoffmann A, Horvath T, Oberholzer M, Arnold M, Pilgram-pastor SM. Stroke and splenic infarct in a 17-year-old patient with COVID-associated hypercoagulable state and relative ADAMTS13 deficiency. Clinical and Translational Neuroscience 2021;5:2514183X2110201. [DOI: 10.1177/2514183x211020157] [Reference Citation Analysis]
65 Chang JC. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy. Vasc Health Risk Manag 2021;17:273-98. [PMID: 34103921 DOI: 10.2147/VHRM.S299357] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
66 Philippe A, Gendron N, Bory O, Beauvais A, Mirault T, Planquette B, Sanchez O, Diehl JL, Chocron R, Smadja DM. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance. Angiogenesis 2021;24:407-11. [PMID: 33974165 DOI: 10.1007/s10456-021-09789-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
67 Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 2021;18:666-82. [PMID: 33958774 DOI: 10.1038/s41569-021-00552-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 58] [Article Influence: 5.0] [Reference Citation Analysis]
68 Mei ZW, van Wijk XMR, Pham HP, Marin MJ. Role of von Willebrand Factor in COVID-19 Associated Coagulopathy. J Appl Lab Med 2021:jfab042. [PMID: 33930144 DOI: 10.1093/jalm/jfab042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Dhingra G, Maji M, Mandal S, Vaniyath S, Negi G, Nath UK. COVID 19 infection associated with thrombotic thrombocytopenic purpura. J Thromb Thrombolysis 2021. [PMID: 33904053 DOI: 10.1007/s11239-021-02452-0] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
70 Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost 2021;47:400-18. [PMID: 33893632 DOI: 10.1055/s-0041-1727282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
71 Marco A, Marco P. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19. J Thromb Thrombolysis 2021. [PMID: 33866481 DOI: 10.1007/s11239-021-02457-9] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
72 Kalbhenn J, Glonnegger H, Wilke M, Bansbach J, Zieger B. Hypercoagulopathy, acquired coagulation disorders and anticoagulation before, during and after extracorporeal membrane oxygenation in COVID-19: a case series. Perfusion 2021;36:592-602. [PMID: 33719738 DOI: 10.1177/02676591211001791] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
73 Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kelton JG, Arnold DM. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost 2021;19:1342-7. [PMID: 33639037 DOI: 10.1111/jth.15283] [Cited by in Crossref: 20] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
74 Matsuishi Y, Mathis BJ, Shimojo N, Subrina J, Okubo N, Inoue Y. Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. Biomedicines 2021;9:279. [PMID: 33801921 DOI: 10.3390/biomedicines9030279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
75 Akhter MS, Hamali HA, Mobarki AA, Rashid H, Oldenburg J, Biswas A. SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. J Clin Med 2021;10:1064. [PMID: 33806540 DOI: 10.3390/jcm10051064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
76 de Carranza M, Salazar DE, Troya J, Alcázar R, Peña C, Aragón E, Domínguez M, Torres J, Muñoz-Rivas N. Aortic thrombus in patients with severe COVID-19: review of three cases. J Thromb Thrombolysis 2021;51:237-42. [PMID: 32648092 DOI: 10.1007/s11239-020-02219-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
77 Bornstein R, Páramo JA. Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19? J Thromb Thrombolysis 2021;51:633-6. [PMID: 32785830 DOI: 10.1007/s11239-020-02247-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]